Zynerba Pharma (ZYNE) Pivotal CONNECT-FX Trial of Zygel in Fragile X Syndrome Did Not Achieve Statistical Significance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. DFTX
9. NAVN
10. IBM

Go back to Zynerba Pharma (ZYNE) Pivotal CONNECT-FX Trial of Zygel in Fragile X Syndrome Did Not Achieve Statistical Significance

Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome

June 30, 2020 6:46 AM EDT

- Study Did Not Achieve Statistical Significance in Primary or Key Secondary Endpoints in Full Analysis Set -

- Achieved Statistical Significance on Primary Endpoint (p=0.020) in Pre-Planned Ad Hoc Analysis of Patients with Full Methylation of the FMR1 Gene Comprising 80% of the Study Population -

- Zynerba to host conference call and webcast today, June 30, 2020 at 8:30 am ET -

DEVON, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare... More